International Society for the Systems Sciences     

                    Berlin  Symposium  August 2-7, 2015

                         Humboldt University, Berlin

 

      Fundamental Shift In Cancer Management Program 

 

Elior L. Kinarthy, PhD

Professor of Psychology (emeritus)

Rio Hondo College, California

www.cancer-vcrc.org

 

Abstract

Better cancer screening and advances in various treatments have increased the survival rate of the majority of cancer patients to over five years. The purpose of this pilot case study is to demonstrate that with a restructured cancer management system the survival rate of a male patient with bone metastatic prostate cancer can potentially exceed 15 years. The fundamental shift in the cancer management begins from ground zero, a practical integration of western and eastern systems of treating cancer.

        This 15-year case study uses Nobel laureate Daniel Kahneman’s “System 1 and System 2” decision making process (Thinking, Fast and Slow, Doubleday, Canada, 2011). These systems of thinking can be used for adjusting the doctors’ orders to fit the patient’s needs. The goal is to select the most effective treatment management for that patient in an optimal support environment. The focus is the patient as a client participant. The method for treating cancer successfully requires new proactive rules of behaviour at home and at clinics and hospitals. The functional framework for treating cancer successfully requires adopting new roles of behaviour for the patient as a proactive client, the physician as an effective communicator and administrator of treatments, and the family, friends and the patients as a socio-emotive support group.

        The effectiveness of the new system requires participation by all practitioners in a cancer client advocacy workshop run by a trained holistic case management technician that ensures that complementary treatments such as CBD (Cannabidiol), DCT (Dendritic Cell Therapy), hyperthermia, meditation, infusions, Proton radiation, green tea (Gyokuro), Ginger, Turmeric and others are considered, that there is a balance in the use of Allopathic, holistic, alternative and complementary treatments. All treatments must be “designed” for the patient-client taking into consideration age, culture, sex, emotional state, knowledge and expectation. The system must assure that the patient-client financial concerns don’t add additional stress and the place of residency is adequate while receiving treatments.

        The success of this complex new system of cancer management depends on professional advocacy.  The advocacy must be a Yin-Yang balanced and harmonious symbiotic mix of western and eastern medicine, allopathic-holistic and traditional and complementary treatments.  This practical application of this conceptual model of treating cancer patients as cancer clients was based on a 15-year case study by a psychologist. The criterion  validity of this case study was established by examining the relationship between various traditional-complementary treatment modalities and their outcome as measured by blood tests, MRI, CT, PSA, Testosterone level and other biomarkers. Reliability has been established by repeated measurements. The results of this case study show that the patient as a participating client improved self-confidence, assertiveness, spirituality and prognosis. The new treatment model worked to effectively arrest cancer growth although some of the allopathic physicians disagreed with the changes in the treatment protocol initiated by the patient.

         At the beginning of treatment a large tumour appeared in the prostate and metastasized to spinal lumbar vertebrae 10, 11, and 12. The prostate tumour was gone with 9 weeks of proton radiation treatment in California and extensive acupuncture to reduce pain, the metastasis was gone with 4 yearly dendritic and hyperthermia treatments in Cologne, Germany and the spinal bone tumour was removed surgically in Canada. Remission was demonstrated by successive MRI reports for the last 5 years. PSA reduction from 60 mg/mL to 0.01 mg/mL was shown by successive blood tests. It took 10 years to get to remission. Follow up tests shows no reoccurrence of cancer after 5 years.